New scan may tell how aggressive your kidney tumor is

NCT ID NCT07346404

Not yet recruiting Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special PET scan using 82-Rb can tell how aggressive a kidney tumor is. Doctors will compare the scan results to the actual tumor grade after surgery. If it works, patients might avoid unnecessary biopsies or surgeries. The study involves 50 adults with suspected or confirmed kidney cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 82-Rb injection
What this could lead to: If successful, this scan could help doctors determine kidney cancer aggressiveness without needing a biopsy or surgery.
What could go wrong: This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The scan may not reliably distinguish between low- and high-grade tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neovascularization, Pathologic renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

AP-HP - hôpital européen Georges-Pompidou

Paris, France
AP-HP - hôpital européen Georges-Pompidou

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.